Indian pharmaceutical firm Dr Reddy’s Laboratories has signed an agreement with SkyePharma giving it access to two of the UK firm’s drug delivery systems.
Very few details of the deal were disclosed and the Hyderabad-headquartered group merely noted that it involves “a feasibility study of a product utilising two of SkyePharma’s proprietary drug delivery systems. The costs of this study will be paid by Dr Reddy’s and its new partner will receive an undisclosed upfront payment.
If the feasibility study is successful, full development activities will begin later this year, Dr Reddy’s said, and there is scope for extending the collaboration at a later date.
The Dr Reddy’s deal was a welcome piece of good news for SkyePharma in the week that the US Food and Drug again delayed a decision on approval of an extended-release version of GlaxoSmithKline’s Parkinson’s disease drug (ropinirole), the technology for which has been licensed from SkyePharma.
